RAPID COVID-19 ANTIBODY TEST
COVID-19 is a new strain of coronavirus that has not been previously identified in humans: Coronavirus (COVID-19) or SARS-CoV-2, 2019 NovelCoronavirus is a new respiratory virus that can affect your lungs and
airways. This virus is known to cause similar illness ranging from cough, sore throat, diarrhea, nausea, headache, loss of smell or taste, chest pain that is sharp, fever that is higher in severe cases and later confusion. It is like the severe diseases such as Severe Acute Respiratory Syndrome (SARS)
and Middle East Respiratory Syndrome (MERS), but maybe half of people have minor to no symptoms and can still infect others. Many other diseases cause similar symptoms.
FDA Approval for this COVID-19 IgM/IgG Rapid Antibody Test has been submitted under the EUA. They are manufactured in cooperation with a CLIA Certified lab in the USA.
RESULTS IN 15 MIN
ABOUT THE TEST AND COVID 19 (2019nCoV)
The COVID19 IgG/IgM Rapid Test is a 10 minute simple test using lateral flow immunoassay that detects the presence of IgG and IgM antibodies specific to 2019n-CoV. This can be done by a finger prick or a blood draw.
Coronaviruses are enveloped RNA viruses that are distributed broadly among humans, other mammals, and birds and that cause respiratory, gastrointestinal, liver, and neurologic diseases. Six coronavirus species are known to cause human disease. Four viruses — 229E, OC43, NL63, and HKU1 — are prevalent and typically cause common cold symptoms in immunocompetent individuals or children.
1. The COVID19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is for in vitro diagnostic use only. This test should be used for detection of IgG and IgM antibody to 2019-nCoV in whole blood, serum or plasma specimens. Neither the quantitative value nor the rate of increase in the concentration of IgG or IgM antibodies to 2019-nCoV can be determined by this qualitative test.
2. The COVID19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma) will only indicate the presence of IgG and IgM antibodies to 2019-nCoV in the specimen and should not be used as the sole criteria for the diagnosis of 2019-nCoV infections.
3. As with all diagnostic tests, all results must be considered with other clinical information available to the physician.
4. If the test result is negative and clinical symptoms persist, additional follow-up testing using other clinical methods is suggested. A negative result at any time does not preclude the possibility of 2019-nCoV infection.
5. The hematocrit level of the whole blood can affect the test results. Hematocrit level needs to be between 25% and 65% for accurate results.
6. The test will show negative results under the following conditions: The titer of the novel coronavirus antibodies in the sample is lower than the minimum detection limit of the test, or the novel coronavirus antibody has not appeared at the time of sample collection (Asymptomatic stage).
The clinical performance of the “COVID19 IgG/IgM Rapid Test Cassette” was evaluated in Shanghai, China with clinical samples derived from blood samples collected from 2019n-CoV infectious patients and 2019n-CoV non-infectious patients confirmed by PCR. The study included testing of 20 known positive samples and 50 known negative samples. Of the 20 known positive samples, the IgG test yields a 100% agreement of 20 out of 20, while the IgM test yields an 85% agreement of 17 out of 20. Of the 50 known negative samples, the IgG test yields a 98% agreement of 49 out of 50, while the IgM test yields a 96% agreement of 48 out of 50. The “COVID19 IgG/IgM Rapid Test Cassette” (Whole Blood/Serum/Plasma) has been tested against anti-influenza A virus, anti-influenza B virus, anti-RSV, anti-Adenovirus, HBsAg, anti-Syphilis, anti-H. Pylori, anti-HIV and anti-HCV positive specimens. The results showed no cross-reactivity
FOTONA PIANO MODE for Immune prophylaxis
There is evidence that photobiomodulation will boost your immune system. The PIANO mode falls in the range of a “distinct class of laser, a low-power, continuous wave (CW) near-infrared (NIR) invisible laser between 1061–1301 nm” that “significantly enhances the immune response (Kimizuka, 2018).” this was used in vaccine augmentation and dermal effects. The 1064 nm of the PIANO mode can go deep enough to achieve stem cell (SC) stimulation(Khacho,2016; Abrahamse,2017) as well as dendritic and mast cells. The adjuvant effect of NIR laser in the context of intradermal vaccination functionally depends on Mast Cells in skin(Kimizuka, 2018). In addition,the CoolTone by concentric contractions of the muscle release myokine 6 which is actually non inflammatory IL-6.
The abdomen with the R33, 34 handpiece, could be a smaller area, as the randomness of the movement will be our friend. With the L-runner a larger area like six squares will need to be treated and keep the scanner moving slowly as to not give too much energy in one area. A treatment of a muscle group with the CoolTone should increase IL-6 and have immunohealth benefits.
Once infected there are two types of respiratory failure. One that seems to progress very rapidly with low viral titters, and another that has high viral titters and lingers for weeks on a ventilator. Tocilizumab (Actemra an interleukin-6 receptor antagonist) may prevent the Cytokine Release Syndrome, which may be causing the resp failure @ 8 mg/kg IV once; maybe administered alone or in combination with corticosteroids. If there is an overwhelming cytokine storm in the lungs, which is the 2nd group, it should help, but due to viral load may still have the virus to contend with. The first group maybe are the ones that have a rapid response to tocilizumab because it is actually a hypoventilation from encephalitis or neural inflammatory blockade of the synaptic connected route to the medullary cardiorespiratory center (Wiley). I think the Fotona laser could treat these people to modulate the IL-6 inflammation and cytokine storm. This would only be optical penetration of the energy and resets the cytokine regulation. A lot of patients in the hot spots are being sent home and sometimes crash before they make it back, or deteriorate rapidly after being on oxygen or ventilator a few days. If they could be biomodulated prior it could stop this outcome. I think this is mostly a post inflammatory problem and not ongoing viral pathology.
Lasers in the 660nm range have been used for ARDS intrabronchial, but the laser from Fotona 1064 has a very long pulse duration and can penetrate 3 cm into the lungs across the skin and may be able to modulate the inflammation externally over the chest wall and within hours an effect on ventilator setting should be observed. This is optical penetration with minimal thermal effect except to the skin, but no risk for burns. The treatments would be brief and could be done 110 V (Time Walker). This type of laser is non contact and high power with a long pulse duration.
I read about Cameron Kyle-Sidell MedScape, and came across an article in Wiley about possible neuroinvasion of SARS‐CoV‐2‐ and the induced respiratory failure. That is what prompted my thoughts. The high numbers in NYC seem that a quick non-invasive treatment that could keep patients off ventilators would be great. It may not work because the energy may have to be adjusted upwards. With photobiomodulation too much energy can autoregulate its effect and shut it off, so it would need to start low and go higher.
I leave some info about photobiomodulation (PBM) and ARDS though Fotona Nd:YAG 1064 not the same thing and typically needs lower energies for PBM.
For the go home respiratory failure, which is a happy hypoxic patient without tachycardia or apprehension, they could be treated like a NightLase treatment but with Nd:YAG not the Erbium.
R33 oral aim towards medulla 150J 6sec, 9mm J for 2000 to 3000 pulses or 5400 J -8000 J. Use the temp sensor to not go above 42 deg, and use a circular pattern in an arching focus on the medulla. If done while on EEG then the changes seen could indicate sufficient energy. Sternal irradiation at higher energies maybe helpful in post Covid cardiomyopathy and myocarditis.